MedTrace Logo

Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia

NCT01848730 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2014-10-30

No results posted yet for this study

Summary

To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in post-herpetic neuralgia (PHN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline period.

Conditions

  • Post-herpetic Neuralgia

Interventions

DRUG

CNV2197944

DRUG

Placebo

Sponsors & Collaborators

  • Convergence Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Milton Raff, MD · Christiaan Barnard Memorial Hospital, Cape Town, South Africa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-02-28
Completion
2014-05-31

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01848730 on ClinicalTrials.gov